Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 363

1.

Serum neurofilaments as candidate biomarkers of natalizumab-PML.

Loonstra FC, Verberk IMW, Wijburg MT, Wattjes MP, Teunissen CE, van Oosten BW, Uitdehaag BMJ, Killestein J, van Kempen ZLE.

Ann Neurol. 2019 Jun 13. doi: 10.1002/ana.25523. [Epub ahead of print] No abstract available.

PMID:
31192473
2.

Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.

Dekker I, Leurs CE, Hagens MHJ, van Kempen ZLE, Kleerekooper I, Lissenberg-Witte BI, Barkhof F, Uitdehaag BMJ, Balk LJ, Wattjes MP, Killestein J.

Mult Scler Relat Disord. 2019 May 28;33:82-87. doi: 10.1016/j.msard.2019.05.017. [Epub ahead of print]

PMID:
31174043
3.

Saccadic fatigability in the oculomotor system.

Nij Bijvank JA, van Rijn LJ, Kamminga M, Tan HS, Uitdehaag BMJ, Petzold A, Balk LJ.

J Neurol Sci. 2019 Jul 15;402:167-174. doi: 10.1016/j.jns.2019.05.024. Epub 2019 May 23.

PMID:
31154074
4.

Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Leurs CE, Twaalfhoven H, Lissenberg-Witte BI, van Pesch V, Dujmovic I, Drulovic J, Castellazzi M, Bellini T, Pugliatti M, Kuhle J, Villar LM, Alvarez-Cermeño JC, Alvarez-Lafuente R, Hegen H, Deisenhammer F, Walchhofer LM, Thouvenot E, Comabella M, Montalban X, Vécsei L, Rajda C, Galimberti D, Scarpini E, Altintas A, Rejdak K, Frederiksen JL, Pihl-Jensen G, Jensen P, Khalil M, Voortman MM, Fazekas F, Saiz A, La Puma D, Vercammen M, Vanopdenbosch L, Uitdehaag B, Killestein J, Bridel C, Teunissen C.

Mult Scler. 2019 May 8:1352458519845844. doi: 10.1177/1352458519845844. [Epub ahead of print]

PMID:
31066634
5.

Diagnosing and quantifying a common deficit in multiple sclerosis: Internuclear ophthalmoplegia.

Nij Bijvank JA, van Rijn LJ, Balk LJ, Tan HS, Uitdehaag BMJ, Petzold A.

Neurology. 2019 May 14;92(20):e2299-e2308. doi: 10.1212/WNL.0000000000007499. Epub 2019 Apr 19.

PMID:
31004067
6.

Quantification of Visual Fixation in Multiple Sclerosis.

Nij Bijvank JA, Petzold A, Coric D, Tan HS, Uitdehaag BMJ, Balk LJ, van Rijn LJ.

Invest Ophthalmol Vis Sci. 2019 Apr 1;60(5):1372-1383. doi: 10.1167/iovs.18-26096. Erratum in: Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2571.

PMID:
30938772
7.

High work absence around time of diagnosis of multiple sclerosis is associated with fatigue and relapse rate.

Doesburg D, Vennegoor A, Uitdehaag BMJ, van Oosten BW.

Mult Scler Relat Disord. 2019 Jun;31:32-37. doi: 10.1016/j.msard.2019.03.011. Epub 2019 Mar 16.

PMID:
30901702
8.

Evaluation of the content coverage of questionnaires containing basic and instrumental activities of daily living (ADL) used in adult patients with brain tumors.

Oort Q, Taphoorn MJB, Sikkes SAM, Uitdehaag BMJ, Reijneveld JC, Dirven L.

J Neurooncol. 2019 May;143(1):1-13. doi: 10.1007/s11060-019-03136-9. Epub 2019 Mar 18. Review.

9.

Setwise comparison: efficient fine-grained rating of movement videos using algorithmic support - a proof of concept study.

Steinheimer S, Dorn JF, Morrison C, Sarkar A, D'Souza M, Boisvert J, Bedi R, Burggraaff J, Kontschieder P, Dahlke F, Sellen A, Uitdehaag BMJ, Kappos L, Kamm CP.

Disabil Rehabil. 2019 Feb 20:1-7. doi: 10.1080/09638288.2018.1563832. [Epub ahead of print]

PMID:
30782055
10.

Treatment of internuclear ophthalmoparesis in multiple sclerosis with fampridine: A randomized double-blind, placebo-controlled cross-over trial.

Kanhai KMS, Nij Bijvank JA, Wagenaar YL, Klaassen ES, Lim K, Bergheanu SC, Petzold A, Verma A, Hesterman J, Wattjes MP, Uitdehaag BMJ, van Rijn LJ, Groeneveld GJ.

CNS Neurosci Ther. 2019 Jun;25(6):697-703. doi: 10.1111/cns.13096. Epub 2019 Feb 12.

PMID:
30756475
11.

[Paroxysmal hypothermia in multiple sclerosis].

De Kleermaeker FGCM, Uitdehaag BMJ, van Oosten BW, van Munster CEP.

Ned Tijdschr Geneeskd. 2019 Jan 14;163. pii: D3116. Dutch.

PMID:
30676705
12.

Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ).

van Munster CE, Kaya L, Obura M, Kalkers NF, Uitdehaag BM.

Mult Scler. 2019 Jan 18:1352458518823489. doi: 10.1177/1352458518823489. [Epub ahead of print]

PMID:
30657002
13.

Predicting clinical progression in multiple sclerosis after 6 and 12 years.

Dekker I, Eijlers AJC, Popescu V, Balk LJ, Vrenken H, Wattjes MP, Uitdehaag BMJ, Killestein J, Geurts JJG, Barkhof F, Schoonheim MM.

Eur J Neurol. 2019 Jun;26(6):893-902. doi: 10.1111/ene.13904. Epub 2019 Feb 2.

PMID:
30629788
14.

Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.

Naegelin Y, Naegelin P, von Felten S, Lorscheider J, Sonder J, Uitdehaag BMJ, Scotti B, Zecca C, Gobbi C, Kappos L, Derfuss T.

JAMA Neurol. 2019 Jan 7. doi: 10.1001/jamaneurol.2018.4239. [Epub ahead of print]

PMID:
30615019
15.

Acid sphingomyelinase: No potential as a biomarker for multiple sclerosis.

Leurs CE, Lopes Pinheiro MA, Wierts L, den Hoedt S, Mulder MT, Eijlers AJC, Schoonheim MM, Balk LJ, Uitdehaag BMJ, Killestein J, de Vries HE.

Mult Scler Relat Disord. 2019 Feb;28:44-49. doi: 10.1016/j.msard.2018.11.024. Epub 2018 Nov 30.

PMID:
30553168
16.

Resting-state MEG measurement of functional activation as a biomarker for cognitive decline in MS.

Schoonhoven DN, Fraschini M, Tewarie P, Uitdehaag BM, Eijlers AJ, Geurts JJ, Hillebrand A, Schoonheim MM, Stam CJ, Strijbis EM.

Mult Scler. 2018 Nov 22:1352458518810260. doi: 10.1177/1352458518810260. [Epub ahead of print]

PMID:
30465461
17.

Development of the Arm Function in Multiple Sclerosis Questionnaire-Short Form (AMSQ-SF): A static 10-item version.

Luijten MA, Eekhout I, D'Hooghe M, Uitdehaag BM, Mokkink LB.

Mult Scler. 2018 Nov 9:1352458518808197. doi: 10.1177/1352458518808197. [Epub ahead of print]

18.

Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.

Eijlers AJC, van Geest Q, Dekker I, Steenwijk MD, Meijer KA, Hulst HE, Barkhof F, Uitdehaag BMJ, Schoonheim MM, Geurts JJG.

Brain. 2018 Sep 1;141(9):2605-2618. doi: 10.1093/brain/awy202.

PMID:
30169585
19.

Tasks of activities of daily living (ADL) are more valuable than the classical neurological examination to assess upper extremity function and mobility in multiple sclerosis.

van Munster CE, D'Souza M, Steinheimer S, Kamm CP, Burggraaff J, Diederich M, Kravalis K, Dorn J, Walsh L, Dahlke F, Kappos L, Uitdehaag BM.

Mult Scler. 2018 Aug 31:1352458518796690. doi: 10.1177/1352458518796690. [Epub ahead of print]

20.

Reference videos reduce variability of motor dysfunction assessments in multiple sclerosis.

D'Souza M, Steinheimer S, Dorn J, Morrison C, Boisvert J, Kravalis K, Burggraaff J, van Munster CE, Diederich M, Sellen A, Kamm CP, Dahlke F, Uitdehaag BM, Kappos L.

Mult Scler J Exp Transl Clin. 2018 Aug 9;4(3):2055217318792399. doi: 10.1177/2055217318792399. eCollection 2018 Jul-Sep.

21.

Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.

Wijburg MT, Warnke C, Barkhof F, Uitdehaag BMJ, Killestein J, Wattjes MP.

J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):44-46. doi: 10.1136/jnnp-2018-318261. Epub 2018 Aug 12.

PMID:
30100552
22.

Natural History of Vanishing White Matter.

Hamilton EMC, van der Lei HDW, Vermeulen G, Gerver JAM, Lourenço CM, Naidu S, Mierzewska H, Gemke RJBJ, de Vet HCW, Uitdehaag BMJ, Lissenberg-Witte BI; VWM Research Group, van der Knaap MS.

Ann Neurol. 2018 Aug;84(2):274-288. doi: 10.1002/ana.25287. Epub 2018 Sep 6.

23.

A standardized protocol for quantification of saccadic eye movements: DEMoNS.

Nij Bijvank JA, Petzold A, Balk LJ, Tan HS, Uitdehaag BMJ, Theodorou M, van Rijn LJ.

PLoS One. 2018 Jul 16;13(7):e0200695. doi: 10.1371/journal.pone.0200695. eCollection 2018.

24.

Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis.

Uitdehaag BMJ.

CNS Drugs. 2018 Jun;32(6):543-558. doi: 10.1007/s40263-018-0530-8. Review.

25.

Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.

Piena MA, Heisen M, Wormhoudt LW, Wingerden JV, Frequin STFM, Uitdehaag BMJ.

J Med Econ. 2018 Oct;21(10):968-976. doi: 10.1080/13696998.2018.1489255. Epub 2018 Jul 9.

PMID:
29911917
26.

The clinical value of the patient-reported multiple sclerosis neuropsychological screening questionnaire.

Nauta IM, Balk LJ, Sonder JM, Hulst HE, Uitdehaag BM, Fasotti L, de Jong BA.

Mult Scler. 2018 May 1:1352458518777295. doi: 10.1177/1352458518777295. [Epub ahead of print]

PMID:
29775164
27.

Progression of regional grey matter atrophy in multiple sclerosis.

Eshaghi A, Marinescu RV, Young AL, Firth NC, Prados F, Jorge Cardoso M, Tur C, De Angelis F, Cawley N, Brownlee WJ, De Stefano N, Laura Stromillo M, Battaglini M, Ruggieri S, Gasperini C, Filippi M, Rocca MA, Rovira A, Sastre-Garriga J, Geurts JJG, Vrenken H, Wottschel V, Leurs CE, Uitdehaag B, Pirpamer L, Enzinger C, Ourselin S, Gandini Wheeler-Kingshott CA, Chard D, Thompson AJ, Barkhof F, Alexander DC, Ciccarelli O.

Brain. 2018 Jun 1;141(6):1665-1677. doi: 10.1093/brain/awy088.

28.

Fronto-limbic disconnection in patients with multiple sclerosis and depression.

van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, Smit JH, Uitdehaag BM, Geurts JJ, van Oppen P, Hulst HE.

Mult Scler. 2019 Apr;25(5):715-726. doi: 10.1177/1352458518767051. Epub 2018 Mar 28.

29.

Software updates of OCT segmentation algorithms influence longitudinal assessment of retinal atrophy.

Coric D, Petzold A, Uitdehaag BMJ, Balk LJ.

J Neurol Sci. 2018 Apr 15;387:16-20. doi: 10.1016/j.jns.2018.01.020. Epub 2018 Feb 3.

PMID:
29571856
30.

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study.

Miller DH, Lublin FD, Sormani MP, Kappos L, Yaldizli Ö, Freedman MS, Cree BAC, Weiner HL, Lubetzki C, Hartung HP, Montalban X, Uitdehaag BMJ, MacManus DG, Yousry TA, Gandini Wheeler-Kingshott CAM, Li B, Putzki N, Merschhemke M, Häring DA, Wolinsky JS.

Ann Clin Transl Neurol. 2018 Jan 30;5(3):346-356. doi: 10.1002/acn3.534. eCollection 2018 Mar.

31.

Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, de Vos M, Warnke C, Uitdehaag BMJ, Barkhof F, Killestein J, Wattjes MP.

JAMA Neurol. 2018 Jul 1;75(7):827-833. doi: 10.1001/jamaneurol.2018.0094.

32.

The role of the cerebellum in multiple sclerosis-150 years after Charcot.

Parmar K, Stadelmann C, Rocca MA, Langdon D, D'Angelo E, D'Souza M, Burggraaff J, Wegner C, Sastre-Garriga J, Barrantes-Freer A, Dorn J, Uitdehaag BMJ, Montalban X, Wuerfel J, Enzinger C, Rovira A, Tintore M, Filippi M, Kappos L, Sprenger T; MAGNIMS study group.

Neurosci Biobehav Rev. 2018 Jun;89:85-98. doi: 10.1016/j.neubiorev.2018.02.012. Epub 2018 Feb 23. Review.

PMID:
29477616
33.

Explaining the heterogeneity of functional connectivity findings in multiple sclerosis: An empirically informed modeling study.

Tewarie P, Steenwijk MD, Brookes MJ, Uitdehaag BMJ, Geurts JJG, Stam CJ, Schoonheim MM.

Hum Brain Mapp. 2018 Jun;39(6):2541-2548. doi: 10.1002/hbm.24020. Epub 2018 Feb 21.

34.

Anxiety is more important than depression in MS - Commentary.

de Jong BA, Uitdehaag BM.

Mult Scler. 2018 Apr;24(4):444-445. doi: 10.1177/1352458518756516. Epub 2018 Jan 30. No abstract available.

35.

Disease activity following pregnancy-related discontinuation of natalizumab in MS.

Kleerekooper I, van Kempen ZLE, Leurs CE, Dekker I, Rispens T, Lissenberg-Witte BI, van Munster CEP, de Jong BA, van Oosten BW, Uitdehaag BMJ, Wattjes MP, Killestein J.

Neurol Neuroimmunol Neuroinflamm. 2017 Dec 5;5(1):e424. doi: 10.1212/NXI.0000000000000424. eCollection 2018 Jan.

36.

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, Brownlee W, Drulovic J, Montalban X, Cramer SP, Pichler A, Hagens M, Ruggieri S, Martinelli V, Miszkiel K, Tintorè M, Comi G, Dekker I, Uitdehaag B, Dujmovic-Basuroski I, Rocca MA.

Lancet Neurol. 2018 Feb;17(2):133-142. doi: 10.1016/S1474-4422(17)30469-6. Epub 2017 Dec 21.

PMID:
29275979
37.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
38.

Does the presence of multiple sclerosis impact on symptom profile in depressed patients?

Boeschoten RE, Schaakxs R, Dekker J, Uitdehaag BMJ, Beekman ATF, Smit JH, Penninx BWJH, van Oppen P.

J Psychosom Res. 2017 Dec;103:70-76. doi: 10.1016/j.jpsychores.2017.10.006. Epub 2017 Oct 12.

PMID:
29167049
39.

Cognitive rehabilitation and mindfulness in multiple sclerosis (REMIND-MS): a study protocol for a randomised controlled trial.

Nauta IM, Speckens AEM, Kessels RPC, Geurts JJG, de Groot V, Uitdehaag BMJ, Fasotti L, de Jong BA.

BMC Neurol. 2017 Nov 21;17(1):201. doi: 10.1186/s12883-017-0979-y.

40.

Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS.

Wattjes MP, Wijburg MT, van Eijk J, Frequin S, Uitdehaag BMJ, Barkhof F, Warnke C, Killestein J; Dutch-Belgian Natalizumab-Associated PML Study Group.

J Neurol Neurosurg Psychiatry. 2018 May;89(5):535-541. doi: 10.1136/jnnp-2017-316886. Epub 2017 Nov 15.

PMID:
29142146
41.

Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis.

Dekker I, Sombekke MH, Witte BI, Geurts JJ, Barkhof F, Uitdehaag BM, Killestein J, Wattjes MP.

Mult Scler. 2018 Apr;24(4):481-490. doi: 10.1177/1352458517736147. Epub 2017 Nov 6. Erratum in: Mult Scler. 2019 Jan;25(1):NP2.

42.

The Arm Function in Multiple Sclerosis Questionnaire was successfully translated to German.

Steinheimer S, Wendel M, Vanbellingen T, Westers LT, Hodak J, Blatter V, Uitdehaag BMJ, Kamm CP.

J Hand Ther. 2018 Jan - Mar;31(1):137-140.e1. doi: 10.1016/j.jht.2017.09.010. No abstract available.

PMID:
29102479
43.

Structure-function relationships in the visual system in multiple sclerosis: an MEG and OCT study.

Tewarie P, Balk LJ, Hillebrand A, Steenwijk MD, Uitdehaag BMJ, Stam CJ, Petzold A.

Ann Clin Transl Neurol. 2017 Jul 25;4(9):614-621. doi: 10.1002/acn3.415. eCollection 2017 Sep.

44.

Diagnostic accuracy of optical coherence tomography inter-eye percentage difference for optic neuritis in multiple sclerosis.

Coric D, Balk LJ, Uitdehaag BMJ, Petzold A.

Eur J Neurol. 2017 Dec;24(12):1479-1484. doi: 10.1111/ene.13443. Epub 2017 Oct 9.

PMID:
28887838
45.

SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.

Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL; SUMMIT Consortium.

Mult Scler. 2018 Oct;24(11):1485-1498. doi: 10.1177/1352458517726657. Epub 2017 Aug 29.

PMID:
28847219
46.

Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.

Leurs CE, van Kempen ZL, Dekker I, Balk LJ, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J.

Mult Scler. 2018 Oct;24(11):1453-1460. doi: 10.1177/1352458517726381. Epub 2017 Aug 21.

47.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11.

48.

Five cases of malignant melanoma during fingolimod treatment in Dutch patients with MS.

Killestein J, Leurs CE, Hoogervorst ELJ, van Eijk J, Mostert JP, van den Eertwegh AJM, Uitdehaag BMJ.

Neurology. 2017 Aug 29;89(9):970-972. doi: 10.1212/WNL.0000000000004293. Epub 2017 Aug 2. No abstract available.

PMID:
28768850
49.

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.

Koch MW, Cutter GR, Giovannoni G, Uitdehaag BMJ, Wolinsky JS, Davis MD, Steinerman JR, Knappertz V.

Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4):e358. doi: 10.1212/NXI.0000000000000358. eCollection 2017 Jul.

50.

New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.

Uitdehaag B, Kobelt G, Berg J, Capsa D, Dalén J; European Multiple Sclerosis Platform.

Mult Scler. 2017 Aug;23(2_suppl):117-129. doi: 10.1177/1352458517708663.

PMID:
28643595

Supplemental Content

Loading ...
Support Center